CSI Market
Sign In | Register

Acorda Therapeutics Inc (ACORQ) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ACORQ Annual Cash Flow →
From Acorda Therapeutics Inc through Mar 31 2023, changes in Mar 31 2024's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2024)
3 Months 		(Dec 31 2023) (Sep 30 2023) (Jun 30 2023) (Mar 31 2023)
Operating Activities
Income-27.40
Depreciation & amortization0.88
Amortization of Other Assets5.33
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Finished Goods and Work in Process Inventories2.04
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.13
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase Decrease In Other Inventories-
Increase Decrease In Non Current Deferred Revenue-
Increase Decrease In Non Current Deferred License Revenue-
Increase Decrease In Deferred Revenue Product One-
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Noncurrent-
Non Cash Royalty Revenue-
Increase Decrease In Noncurrent Deferred Cost Of Revenue-
Excess Tax Expense Benefit From Share Based Compensation Operating Activities-
Goodwill And Intangible Asset Impairment-
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability6.24
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable8.11
Increase (Decrease) in Accounts Payable and Accrued Liabilities-10.26
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-4.12
Other Working Capital-1.14
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-20.19
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Acquisitions Net Of Cash Received And Gain On Foreign Currency Transaction-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Treasury Stock Value Acquired Cost Method-
Proceeds From Refund Of Deposit For Purchase Of Non Controlling Interest-
Net Proceeds From Royalty Monetizations-
Proceeds From Sale Of Chelsea Facility Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow-0.09
Discontinued operations0.00
Free Cash Flow-20.19
Total Cash Flow-20.28
4 historic quarters locked

Sign in to unlock the full Acorda Therapeutics Inc cash flow history.

Sign In Create Free Account

About Acorda Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-059114

Figures are derived from filed reports and may be restated. Historical data is subject to revision.